Treatment of Functional Bowel Disorders

This study has been completed.
Sponsor:
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:
NCT00006157
First received: August 8, 2000
Last updated: January 12, 2010
Last verified: January 2010

August 8, 2000
January 12, 2010
July 1996
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00006157 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Treatment of Functional Bowel Disorders
Multicenter Trial of Functional Bowel Disorders

The primary purpose for this study is to compare clinical treatments for patients with functional bowel disorders (irritable bowel syndrome, abdominal pain, painful constipation) in women. We also plan to: 1) determine what clinical features (medical or psychological) determine which patients will improve to these treatments, and 2) understand if there are any physiological features that relate to improvement in symptoms and response to the treatments.

We will compare a psychological treatment (cognitive-behavioral therapy - CBT) with education/attention placebo, and an antidepressant drug (desipramine) with a pill placebo. This is the first large-scale study designed to determine the therapeutic effects of these methods, and to also determine interactions among physiologic measures, psychologic and sociodemographic factors, severity of symptoms, and therapeutic improvement including quality of life.

Female patients (aged 18-65) with FBD (irritable bowel syndrome, painful constipation and/or functional abdominal pain) will be enrolled at UNC-Chapel Hill and Toronto, Canada. A severity index will determine recruitment into the group of moderate FBD (200 patients) and severe FBD (100 patients). Each group will be randomized into the three treatment arms (cognitive-behavioral treatment, desipramine, and education/attention placebo), treated over a 12-week period, and followed for one year. Outcome measures will include symptoms (standardized abdominal pain, stool form and frequency) using diary cards, daily functional status (Sickness Impact Profile), depression (HAM-D) and psychological distress (SCL-90), physiological measures (enhanced rectal motility and visceral sensation), and health care use. Multivariate statistical methods with a hierarchical design will be applied to the data to assure maintenance of statistical power over multiple tests of overlapping groups.

The results of this study should significantly improve our understanding of this complicated syndrome that lowers the quality of life and economic productivity of large numbers of women. The clinical impact of the study, in providing physicians with scientific evidence of the efficacy of treatments of FBD that are commonly used in practice, is significant. We anticipate that this study will provide clinicians with predictors of success among types of FBD patients and types of therapy that will improve symptoms and quality of life, and reduce the health care costs associated with this common syndrome while improving patient-physician satisfaction.

Interventional
Phase 3
Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
  • Irritable Bowel Syndrome
  • Constipation
  • Abdominal Pain
  • Functional Colonic Diseases
  • Drug: Desipramine
  • Behavioral: Cognitive Behavioral Treatment
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
March 2001
Not Provided

Inclusion Criteria:

  • Literate, female patients aged 18-65.
  • Symptoms present at least 2 days/week for greater than 6 months.
  • Diagnosis of functional bowel disorder (to be subcategorized using ''Rome'' Criteria.
  • Moderate (MFBD) or severe (SFBD) functional bowel disorder (FBD) based on the Functional Bowel Disorder Severity Index (FBDSI) developed in our pilot study. SFBD will be defined as a score of 110 and MFBD will be defined as a score between 36 and 110.
  • Discontinuation of all antidepressant medications for at least 3 months.
  • Use of acceptable method of birth control.

Exclusion Criteria:

  • Evidence of lactose intolerance to explain bowel symptoms.
  • Heart disease.
  • Cardiac arrhythmias.
  • Severe psychiatric disorder (e.g., bipolar, suicide attempts).
  • Previous use of desipramine.
  • Glaucoma.
  • Urinary retention.
  • Pregnancy.
  • Alcohol consumption 3oz/day that would preclude participation or prevent data assessment.
  • Systemic gastrointestinal diseases or previous surgery that would interfere with the interpretation of symptoms or physiology.
  • Bipolar disorder.
  • Schizophrenia.
  • Substance abuse/dependency.
  • Previous use of desipramine.
Female
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00006157
FBD (completed), RO1DK49334
Not Provided
Not Provided
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not Provided
Principal Investigator: Douglas A. Drossman, M.D. Univ of North Carolina at Chapel Hill
Study Chair: William E. Whitehead, PhD Univ of North Carolina at Chapel Hill
Study Chair: Brenda Toner, PhD Centre for Addiction and Mental Health, Clark Site
Study Chair: Nick Diamant, MD The Toronto Western Hospital
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP